Glorikian Publications
How the Smartphone Is Transforming Medicine My book has recently…
The Theranos scandal cast a pall over self-testing. The pandemic…
Even as Testing Demand Started to Wane, COVID-19 Drove IPOs…
COVID-19 testing problems started early, U.S. still playing from behind…
New Ventures Funds Rebrands as Scientia Ventures NEW YORK, Oct. 2,…
NextGen Healthcare: The problem isn’t genomics by Harry Glorikian, a…
Listent to Episode Here:Â http://fticorporate.com/podcasts/harry-glorikian/ Diving with Data – Episode 11:…
What we pay for in healthcare is the real question…
Healthcares Digital future: Telemedicine and remote monitoring Every week, news…
MONEYBALL MEDICINE PRICE QUALITY TRANSPARENCY Say you want to open…
Welcome to the age of Moneyball Medicine For several years,…
Harry Glorikian’s love letter to the technology industry It’s the…
Intellectual property considerations for molecular diagnostic development with emphasis on…
MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market How…
The MoneyBall solution to the healthcare crisis Many recent articles…
This is why pre-design research is essential for the IVD…
Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can…
Do You Have the Data to Benefit from a Post-Keytruda…
MDBR Interviews Harry Glorikian About the Growing Significance of In…
Q&A: Healthcare Industry Expert Harry Glorikian Discusses His New IVD…